Shattuck Labs Inc
STTK6.020USD
-0.290-4.60%
交易中 （美東）報價延遲15分鐘
229.24M總市值
虧損本益比TTM
關於 Shattuck Labs Inc 公司
Shattuck Labs, Inc. is a biotechnology company. The Company is engaged in the development of treatments for inflammatory and immune-mediated diseases. Its lead product candidate, SL-325, is a monoclonal antibody that is designed to bind to death receptor 3 (DR3) and inhibit its interaction with its ligand, TL1A. TL1A is a costimulatory ligand in the tumor necrosis factor superfamily, which activates immune responses through binding a single receptor, DR3. The Company is conducting a Phase I clinical trial in healthy volunteers. In addition, the Company is also developing SL-425, a half-life extended version of SL-325. It is also developing multiple preclinical DR3-based bispecific antibodies, which are designed to inhibit both the DR3/TL1A axis and another biologically relevant target for the treatment of patients with inflammatory bowel disease.
Shattuck Labs Inc簡介
公司代碼STTK
公司名稱Shattuck Labs Inc
上市日期Oct 09, 2020
CEOSchreiber (Taylor)
員工數量44
證券類型Ordinary Share
年結日Oct 09
公司地址500 W. 5Th Street
城市AUSTIN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編78701
電話15129004690
網址https://www.shattucklabs.com/
公司代碼STTK
上市日期Oct 09, 2020
CEOSchreiber (Taylor)
Shattuck Labs Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+26.51%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
81.53K
-5.82%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
Mr. Andrew R. Neill
Mr. Andrew R. Neill
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Helen M. Boudreau
Ms. Helen M. Boudreau
Independent Director
Independent Director
--
--
Mr. Conor Richardson, CPA
Mr. Conor Richardson, CPA
Senior Director, Finance & Investor Relations
Senior Director, Finance & Investor Relations
--
--
Dr. Abhinav A. Shukla, Ph.D.
Dr. Abhinav A. Shukla, Ph.D.
Chief Technical Officer
Chief Technical Officer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Taylor Schreiber, M.D., Ph.D.
Dr. Taylor Schreiber, M.D., Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
96.61K
+26.51%
Dr. Stephen Stout, Ph.D.
Dr. Stephen Stout, Ph.D.
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer
81.53K
-5.82%
Dr. George S. Golumbeski, Ph.D.
Dr. George S. Golumbeski, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
54.61K
--
Dr. Neil W. Gibson ,Ph.D.
Dr. Neil W. Gibson ,Ph.D.
Independent Director
Independent Director
52.74K
--
Dr. Arundathy Nirmalini (Lini) Pandite
Dr. Arundathy Nirmalini (Lini) Pandite
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Casi Deyoung
Ms. Casi Deyoung
Chief Business Officer
Chief Business Officer
--
--
收入明細
由於公司未披露，未能獲取相關數據
由於公司未披露，未能獲取相關數據
業務
地區
由於公司未披露，未能獲取相關數據
股東統計
更新時間: 2月19日 週四
更新時間: 2月19日 週四
持股股東
股東類型
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
10.30%
OrbiMed Advisors, LLC
8.81%
Adage Capital Management, L.P.
8.81%
Redmile Group, LLC
7.74%
NEXTBio Capital Management LP
4.40%
其他
59.93%
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
10.30%
OrbiMed Advisors, LLC
8.81%
Adage Capital Management, L.P.
8.81%
Redmile Group, LLC
7.74%
NEXTBio Capital Management LP
4.40%
其他
59.93%
股東類型
持股股東
佔比
Investment Advisor
18.97%
Hedge Fund
18.04%
Investment Advisor/Hedge Fund
17.45%
Private Equity
8.81%
Corporation
8.41%
Family Office
2.28%
Research Firm
1.92%
Individual Investor
1.59%
Pension Fund
0.04%
其他
22.49%
機構持股
更新時間: 1月1日 週四
更新時間: 1月1日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
187
35.93M
56.78%
+4.02M
2025Q3
179
32.72M
51.71%
-1.24M
2025Q2
186
35.33M
73.76%
-6.35M
2025Q1
190
36.10M
75.45%
-5.76M
2024Q4
182
37.00M
77.49%
-7.77M
2024Q3
191
41.87M
87.75%
-1.86M
2024Q2
194
39.66M
83.35%
+16.66K
2024Q1
209
37.10M
79.60%
-1.39M
2023Q4
203
34.54M
71.04%
+5.75M
2023Q3
205
27.35M
64.28%
-7.93M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
OrbiMed Advisors, LLC
6.31M
9.97%
+6.31M
--
Sep 30, 2025
Adage Capital Management, L.P.
6.31M
9.97%
+1.63M
+34.89%
Sep 30, 2025
Redmile Group, LLC
5.54M
8.75%
--
--
Sep 30, 2025
Hornblower Capital Holdings, LLC
2.89M
4.57%
--
--
Apr 01, 2025
Houghton Capital Holdings, LLC
2.61M
4.13%
--
--
Apr 01, 2025
Prosight Capital
5.45M
8.61%
-1.19M
-17.89%
Sep 30, 2025
The Vanguard Group, Inc.
2.13M
3.36%
-19.77K
-0.92%
Sep 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Texas Capital Texas Equity Index ETF
0%
iShares Russell 2000 Value ETF
0%
ProShares UltraPro Russell2000
0%
Dimensional US Core Equity 1 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Morningstar Small-Cap ETF
0%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Texas Capital Texas Small Cap Equity Index ETF
0%
查看更多
Texas Capital Texas Equity Index ETF
佔比0%
iShares Russell 2000 Value ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
Dimensional US Core Equity 1 ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
iShares Morningstar Small-Cap ETF
佔比0%
iShares Russell 2000 ETF
佔比0%
Avantis US Small Cap Equity ETF
佔比0%
iShares Micro-Cap ETF
佔比0%
Texas Capital Texas Small Cap Equity Index ETF
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
除權除息日
類型
比率
暫無數據
公告日期
除權除息日
類型
比率
暫無數據
